Meeting
2023 ASCO Annual Meeting
An application of extrapolating clinical data from single-arm trials to assess comparative effectiveness.
Authors
Kangho Suh
University of Pittsburgh, Pittsburgh, PA
Kangho Suh , Scott David Ramsey , Ashley Kang , Gilbert Ko , Todd E. Williamson , Nick Liao , Sean D. Sullivan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6614)
DOI
10.1200/JCO.2023.41.16_suppl.6614
Abstract #
6614
Poster Bd #
106
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer.
First Author: Kangho Suh
Poster
2022 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: Alexander E. Drilon
Poster
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: David S. Hong
Poster
2023 ASCO Annual Meeting
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
First Author: Maria E. Cabanillas